Lucid Diagnostics (LUCD) Fundamentals 2026 — Revenue Analysis | SniperIQ
Lucid Diagnostics (LUCD) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $98M, trading at $0.96 on the NASDAQ. This SniperIQ fundamentals page covers Lucid Diagnostics's valuation, profitability (net margin -876.7%), revenue ($5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lucid Diagnostics's market cap?
Lucid Diagnostics (LUCD) has a market capitalization of approximately $98M, trading at $0.96 on the NASDAQ. Market cap moves with the live share price.
What is Lucid Diagnostics's P/E ratio?
Lucid Diagnostics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 24.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lucid Diagnostics?
Lucid Diagnostics runs a net profit margin of -876.7%, a gross margin of -40.0%, and an operating margin of -959.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lucid Diagnostics generate?
Lucid Diagnostics reported revenue of $5M for fiscal year 2025, with net income of -$58M and earnings per share (EPS) of -0.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lucid Diagnostics pay a dividend?
Lucid Diagnostics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lucid Diagnostics financially healthy?
Lucid Diagnostics carries a debt-to-equity ratio of 6.70x and a current ratio of 1.07x, with a market beta of 1.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lucid Diagnostics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lucid Diagnostics (LUCD) the key facts are: market cap $98M, revenue $5M, 52-week range 0.9-1.629. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lucid Diagnostics's full fundamentals live
Get Lucid Diagnostics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.